Treatment strategies for C. difficile associated diarrhea

Acta Gastroenterologica Latinoamericana

Volumn 37, Issue 3, 2007, Pages 183-191

  Stepan, Crenguta ^b   Surawicz, Christina M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548729624     PISSN: 03009033     EISSN: 03009033     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. ** Bricker E, Garg R, Nelson R, Loza A, Novak T, Hansen J. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. The Cochrane Database of Systematic Reviews 2005, Issue 1.
2. McDonald LC, et al. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis, (2006).
3. * Poutanen SM, Simor AE. Clostridium difficile - associated diarrhea in adults. CMAJ, 2004;171:51.
4. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346-353.
5. Starr J. Clostridium difficile associated diarrhea: diagnosis and treatment, BMJ, 2005;331:498-501.
6. * Barbut F, Decre D, Lalande V, Burghoffer B, Noussair L, Gigandon A et al. Clinical features of Clostridium difficile associated diarrhea due to binary toxin (actin - specific ADP - ribosyltransferase) producing strains, J Med Microbiol, 2005;54:181-185.
7. Geric B, Rupnik M, Gerding DN, Grabnar M, Johnson S. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol; 2004;53:887-894.
8. Schroeder MS, Clostridium difficile-associated diarrhea, Am Fam Physician, 2005;1,71:921-928.
9. ** Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada, CID, 2005;40:1591-1597.
10. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet; 2001;357:189-193.
11. ** Pepin J, Routhier S, Gagnon S, Brazeau I, Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada, CID, 2006;42:758-764.
12. * Surawicz, CM. Treatment of recurrent Clostridium difficile associated diarrhea, Nat Clin Pract Gastroenterol Hepatol, 2004;1:32-38.
13. Huebner ES, Surawicz CM. Treatment of recurrent Clostridium difficile diarrhea, Gastroenterol Hepatol, 2006;2:203-208.
14. ** McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol, 2005;54:101-111.
15. Tedesco FJ, Gordon D, Forston WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol; 1985;80:867-868.
16. Buggy BP, Fekety R, Silva J Jr. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol 1987;9:155-159.
17. ** McFarland, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease, Am J Gastroenterol, 2002;97:1769-1775.
18. ** Johnson S, Galang M, Schriever C, Kelly C, Gerding D, Rifaximin chaser following standard therapeutic cocktail for breaking the cycle of multiple C. difficile diarrhea recurrences, Am J. Gast. 2006;101:S219.
19. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr. 2000;183:S396-S402.
20. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease, JAMA, 1984;271;1913-1918.
21. * Surawicz CM, McFarland LV, Greenberg RN, The search for a better treatment for recurrent Clostridium difficile disease: Use of high-dose vancomycin combined with Saccharomyces boulardii, CID, 2000;31:1012-1017.
22. Wullt M, Johansson MI, Odenholt I. Lactobacillus plantarum 299v for the Treatment of Recurrent Clostridium difficile-associated Diarrhea: A Double-blind, Placebo-controlled Trial, Scandinavian J Infect Dis, 2003;35:365-367.
23. Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for Clostridium difficile disease. J Med Microbiol 2005;54:905-905.
24. Bowden TA, Mansberger AR, Lykins LE. Pseudomembraneous enterocolitis: mechanism of restoring floral homeostasis. Am J Surg. 1981;47:178-183.
25. Schwan A, Sjölin S, Trottestam U, et al. Relapsing Clostridium difficile entero-colitis cured by rectal infusion of normal faeces. Scand J Infect Dis. 1984;16:211.
26. Tvede M, Rask-Madsen J, Bacteriotherapy for chronic relapsing Clostridium difficile diarrhea in six patients, Lancet, 1989;1:1156-1160.
27. Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol. 2000;95:3283-3285.
28. * Aas J, Gessert CE, Bakken JS, Recurrent Clostridium difficile Colitis: Case Series Involving 18 Patients Treated with Donor Stool Administered via a Nasogastric Tube, CID, 2003;36:580-585.
29. Liacouras CA, Piccoli DA. Whole-bowel irrigation as an adjunct to the treatment of chronic, relapsing Clostridium difficile colitis. J Clin Gastroenterol. 1996;22:186-189.
30. Aronsson B, Granström M, Möllby R, et al. Serum antibody response to Clos-tridium difficile toxins in patients with Clostridium difficile diarrhea. Infection 1986;13:97-101.
31. * Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet 2001;357:189-193.
32. Leung DY, Kelly CP, Boguniewicz M, et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr; 1991;118:633-637.
33. Hassett J, Meyers S, McFarland L, Mulligan M E. Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii. Clin Infect Dis. 1995;20(Suppl. 2):S266-S268.
34. Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut. 1997;41:366-370.
35. Beales ILP. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhea. Gut. 2002;51:456.
36. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhea. J Antimicrob Chemother. 2004;53:882-884.
37. Van Dissel JT, De Groot N, Hensgens CMH, Numan S, Kuijper EJ, Veldkamp P, Van 't Wout J, Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhea: preclinical and preliminary clinical data, Med Microbiol 2005;54:197-205
38. Kotloff KL, Wasserman SS, LosonskyGA, Thomas W, Nichols R et al, Safety and immnogenicity of increasing doses of a C. difficile toxoid vaccine administered to healthy adults. Infect. Immun. 2001;69:988-995.
39. ** Giannasca PJ, Warny M, Active and passive immunization against Clostridium difficile diarrhea and colitis, Vaccine, 2004;22:848-856.
40. Louie TJ, Peppe J, Watt CK, Johnson D, Mohammed R, Dow G et al, Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea, CID 2006;43:411-420.
41. Musher DM, Logan N, Hamill RJ, Dupont HL, Lentnek A, Gupta A, Nitazoxanide for the treatment of Clostridium difficile colitis, CID, 2006;43:421-427.
42. Revill P, Serradell N, Bolos J, Tiacumicin B : Macrolide antibiotic treatment of C. Difficile-associated diarrhea, Drug future, 2006;31:494-497.
43. Louie TJ, Clostridium difficile in clinical practice: increasing rates, more virulent organisms and new therapies on the horizont, Can J Infect Dis Med Microbiol, 2006; 17(suppl B):19B-24B.
44. Boero M, Berti E, Morgando A, et al. Treatment for colitis caused by Clostridium difficile: results of a randomized open study of rifaximin vs. vancomycin. Microbiologia Medica, 1990;5:74-77.
45. Kokkotou E, Mustafa N, O'Brien M, Pothoulakis C, Kelly CP. Rifaximin: a novel nonabsorbed antibiotic therapy for Clostridium difficile-associated diarrhea [poster B-35]. In: Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology (2005)
46. Jokipii AM, Jokipii L, Comparative activity of metronidazole and tinidazole against Clostridium difficile and Paptostreptococcus anaerobius, Antimicrobial agents and chemotherapy 1987;31:183-186.
47. Citron DM, Tyrrell KL, Warren YA, Fernandez H, Merriam CV et al. In vitro activities of tinidazole and metronidazole against Clostridium difficile, Prevotella bivia and Bacteroides fragilis, Anaerobe 2005;11:315-317.
48. Freeman J, Baines SD, Jabes D, Wilcox MH, Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection, JAC 2005;56:517-525.
49. Fulco P, Wenzel RP, Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent, Expert Rev Anti Infect Ther 2006;4:939-945.
50. Orrhage K, Sjöstedt S, Nord CE, Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil, J Antimicrob Chemother 2000;46:603-612.
51. Lewis S, Burmeister S, Brazier J, Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study, Clin Gastroenterol Hepatol 2005;3:442-448.
52. Lewis S, Burmeister S, Cohen S, Brazier J et al. Failure of dietary oligofructose to prevent antibiotic-associated diarrhea, Aliment Pharmacol Ther 2005;21:469-477.